Abstract
Fumagillin, an unstable anti-angiogenesis mycotoxin, was synthesized into a stable lipase-labile prodrug and incorporated into integrin-targeted lipid-encapsulated nanoparticles (αvβ3-Fum-PD NP). Dual anti-angiogenic therapy combining αvβ3-Fum-PD NP with zoledronic acid (ZA), a long-acting osteoclast inhibitor with proposed anti-angiogenic effects, was evaluated. In vitro, αvβ3-Fum-PD NP reduced (P < 0.05) endothelial cell viability without impacting macrophage viability. ZA suppressed (P < 0.05) macrophage viability at high dosages but not endothelial cell proliferation. 3D MR neovascular imaging of rabbit Vx2 tumors showed no effect with ZA, whereas αvβ3-Fum-PD NP alone and with ZA decreased angiogenesis (P < 0.05). Immunohistochemistry revealed decreased (P < 0.05) microvascularity with αvβ3-Fum-PD NP and ZA and further microvascular reduction (P < 0.05) with dual-therapy. In vivo, ZA did not decrease tumor macrophage numbers nor cancer cell proliferation, whereas αvβ3-Fum-PD-NPs reduced both measures. Dual-therapy with ZA and αvβ3-Fum-PD-NP may provide enhanced neo-adjuvant utility if macrophage ZA uptake is increased. From the Clinical Editor: Although anti-angiogenesis is one of the treatment modalities in the fight against cancer, many cancers become resistant to VEGF pathway inhibitors. In this article, the authors investigated the use of dual therapy using fumagillin, integrin-targeted lipid-encapsulated nanoparticles (αvβ3- Fum-PD NP) and zoledronic acid (ZA), in both in-vitro and in-vivo experiments. This combination approach may provide an insight to the design of future drugs against cancers.
Original language | English |
---|---|
Pages (from-to) | 201-211 |
Number of pages | 11 |
Journal | Nanomedicine: Nanotechnology, Biology, and Medicine |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2016 |
Keywords
- Cancer
- Fumagillin
- MRI
- Molecular imaging
- Nanoparticle
- Zoledronic acid